Health

Gozellix Receives Permanent HCPCS Code

MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces…

5 months ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

July 09, 2025 16:16 ET  | Source: Rhythm Pharmaceuticals, Inc. BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.…

5 months ago

Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025

July 09, 2025 16:15 ET  | Source: Certara RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),…

5 months ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

July 08, 2025 21:36 ET  | Source: Cogent Biosciences, Inc. WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE)…

5 months ago

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

5 months ago

AJA Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements

July 08, 2025 16:48 ET  | Source: Aja Health and Wellness Inc. Not for dissemination in the United States of…

5 months ago

UAE Approves BioAros Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health

CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) -- In a significant move that bridges biotechnology, preventive health, and global wellness…

6 months ago

AB Science announces the successful completion of a EUR 1.925 million private placement

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925 MILLION PRIVATE PLACEMENT Paris, July 8, 2025, 8am…

6 months ago

Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a…

6 months ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

6 months ago